These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 511416)

  • 1. Amikacin: in vitro bacteriological studies, levels in human serum, lung and heart tissue, and clinical results.
    Faragó E; Kiss J; Gömöry A; Aranyosi J; Juhász I; Mihóczy L
    Int J Clin Pharmacol Biopharm; 1979 Nov; 17(11):421-8. PubMed ID: 511416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled comparison of amikacin and gentamicin.
    Smith CR; Baughman KL; Edwards CQ; Rogers JF; Lietman PS
    N Engl J Med; 1977 Feb; 296(7):349-53. PubMed ID: 319355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
    Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experimental study of the antibacterial activity and chemotherapeutic effectiveness of amikacin sulfate].
    Lobuseva AN; Kuznetsova SM; Samoĭlova LN
    Antibiot Med Biotekhnol; 1985 Oct; 30(10):776-80. PubMed ID: 4091515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacement of gentamicin by amikacin as a means of decreasing gentamicin resistance of gram-negative rods in a neonatal intensive care unit.
    Wielunsky E; Drucker M; Cohen T; Reisner SH
    Isr J Med Sci; 1983 Nov; 19(11):1006-8. PubMed ID: 6662682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations on the flucloxacillin levels in human serum, lung tissue, pericardial fluid and heart tissue.
    Kiss IJ; Faragó E; Gömöry A; Szamaránszky J
    Int J Clin Pharmacol Ther Toxicol; 1980 Sep; 18(9):405-11. PubMed ID: 7450932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amikacin therapy of severe infections produced by gram-negative bacilli resistant to gentamicin.
    Valdivieso M; Bodey GP
    Am J Med Sci; 1977; 273(2):177-84. PubMed ID: 860733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate.
    Pien FD; Ho PW
    Am J Hosp Pharm; 1981 Jul; 38(7):981-9. PubMed ID: 7020413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data on sisomicin effect: human pharmacokinetic and bacteriological studies.
    Faragó E; Kiss IJ; Mihóczy L
    Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):128-32. PubMed ID: 7380585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Amikacin in the treatment of hospital infections of the urinary tract caused by gram-negative bacilli resistant to gentamicin. Microbiological and clinical aspects].
    Romoli E; Di Leonardo F; Giordano G; De Felice M; Cerquetti F; Vonmoos A
    Minerva Urol; 1981; 33(2):85-90. PubMed ID: 7322100
    [No Abstract]   [Full Text] [Related]  

  • 12. [Dibekacin--a novel aminoglycoside antibioticl. Antimicrobial activity and parallel resistance in vitro].
    Schassan HH; Witt U
    Arzneimittelforschung; 1979; 29(2):174-8. PubMed ID: 582126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical pharmacology of the most frequently used aminoglucosides: gentamycin, tobramycin and amikacin].
    Cuena Boy R; Azanza Perea JR; Echeverría Echepare LM; Honorato Pérez J
    Rev Med Univ Navarra; 1983 Dec; 27(4):21-7. PubMed ID: 6676898
    [No Abstract]   [Full Text] [Related]  

  • 14. Amikacin.
    Gleckman R
    Am Fam Physician; 1976 Dec; 14(6):75. PubMed ID: 998471
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro evaluation of ceftazidime (GR 20263), amikacin and sisomicin, in a model simulating serum pharmacokinetics of therapeutic doses.
    Xerri L; Orsolini P; Broggio R
    Chemioterapia; 1984 Oct; 3(5):271-7. PubMed ID: 6398124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amikacin treatment of pulmonary infections involving gentamicin-resistant gram-negative bacilli.
    Bartlett JG
    Am J Med; 1977 Jun; 62(6):945-8. PubMed ID: 868911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transduction of amikacin, gentamicin and tobramycin resistance in Pseudomonas aeruginosa.
    Knothe H; Krcméry V; Mitsuhashi S
    Zentralbl Bakteriol A; 1980 Mar; 246(3):373-8. PubMed ID: 6775445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of amikacin, gentamicin and kanamycin against Pseudomonas aeruginosa.
    Ximenes J; Bassoi ON; de Menezes JP; Fry W
    J Int Med Res; 1976; 4(3):165-75. PubMed ID: 829072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory and clinical studies on amikacin.
    Wang QN; Du JZ; Liu YH; Jiang YF; Sheng JQ; Qiu ZD; Luo MY
    Chin Med J (Engl); 1985 Nov; 98(11):807-16. PubMed ID: 3938711
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical pharmacokinetics of amikacin in dogs.
    Baggot JD; Ling GV; Chatfield RC
    Am J Vet Res; 1985 Aug; 46(8):1793-6. PubMed ID: 4037511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.